Wednesday, December 9th at 11:00 AM CT
Join us for an exclusive presentation with the CEO of icosiMED.
icosiMED is developing a first-in-class oral therapy that mimics the fasting state by disrupting the conversion of dietary carbohydrates to stored fat, enabling significant fat loss without muscle loss or appetite suppression. Although GLP-1 drugs have expanded the multi-billion-dollar weight management market, an estimated 80% of patients discontinue them and regain weight, and pharmaceutical companies are seeking novel pre-clinical assets beyond this class.